Article Impact Level: HIGH Data Quality: STRONG Summary of Journal of Clinical Microbiology https://doi.org/10.1128/jcm.01823-25 Dr. Chaney C. Kalinich et al.
Points
- Researchers successfully adapted tiled amplicon sequencing to read the whole genome of tuberculosis bacteria directly from clinical sputum samples without requiring a traditional six-week laboratory culture period.
- The team developed a massive panel of five thousand one hundred twenty-eight primers to map the complex bacterial genome which is significantly larger than viral genomes previously studied.
- This innovative diagnostic approach reduces the time needed for comprehensive drug susceptibility testing from several weeks to just a few days while lowering per-sample costs to under twenty dollars.
- Proof-of-concept testing using patient samples from Moldova and Peru confirmed that the method accurately identifies drug-resistance markers and bacterial lineages even in samples with low bacterial concentrations.
- Implementation of this affordable and rapid sequencing technology could drastically improve tuberculosis surveillance and clinical outcomes in high-burden countries like India, Bangladesh, and the Democratic Republic of the Congo
Summary
This study evaluated the adaptation of tiled amplicon sequencing for the whole-genome analysis of Mycobacterium tuberculosis (Mtb) directly from clinical sputum specimens. Traditionally, Mtb genomics requires laboratory incubation for up to six weeks to achieve sufficient bacterial concentrations for sequencing. To bypass this culture-dependent delay, researchers developed a high-density panel consisting of 5,128 primers—the largest known tiled panel to date—designed to cover the entire bacterial genome, which is over 100 times larger than that of the SARS-CoV-2 virus.
Using clinical samples from high-burden regions including Moldova and Peru, the study demonstrated that this method can accurately recover whole-genome sequences within a matter of days. The approach effectively identifies bacterial lineage and critical markers of drug resistance even in samples with low bacterial concentrations or significant environmental contamination. By eliminating the six-week incubation period, the protocol reduces the turnaround time for comprehensive drug susceptibility testing from over a month to just a few days, significantly enhancing the clinical utility of genetic data.
Economically, the tiled amplicon method reduces testing costs from several hundred dollars per sample to less than $20. This drastic reduction in overhead and labor makes whole-genome sequencing accessible for large-scale surveillance in resource-limited settings like India and South Africa, where drug-resistant TB is most prevalent. While further research is required to validate real-world implementation in decentralized laboratories, these findings suggest that culture-free sequencing could transform global tuberculosis control by providing rapid, affordable insights into transmission patterns and resistance epidemiology.
Link to the article: https://journals.asm.org/doi/10.1128/jcm.01823-25
References
Kalinich, C. C., Gonzalez, F. L., Osmaston, A., Breban, M. I., Distefano, I., Leon, C., Coronel, J., Tan, G., Crudu, V., Ciobanu, N., Codreanu, A., Solano, W., Ráez, J., Sheen, P., Zimic, M., Allicock, O. M., Chaguza, C., Wyllie, A. L., Brandt, M., … Redmond, S. N. (2026). A tiled amplicon protocol for culture-free whole-genome sequencing of M. tuberculosis from clinical specimens. Journal of Clinical Microbiology, e01823-25. https://doi.org/10.1128/jcm.01823-25
